0 +

Next-Generation RNA Companion Diagnostics for Accurate, Fast and Simple Cancer Targeted Treatment Decisions
expressTEC is a pioneering biotech startup from the University of Algarve, founded by two visionary women scientists dedicated to transforming cancer care. We proudly offer the first RNA-based test for assessing eligibility for targeted treatments, harnessing RNA analysis to provide a comprehensive view of each patient’s genetic profile. This empowers healthcare providers to make informed, personalized treatment decisions. Our flagship product, expressPIK, precisely identifies the most common mutations found in breast tumors, demonstrating the power of our approach. As a proof of concept, expressPIK represents just the beginning of our broader vision: a robust platform to test multiple mutations across all cancer types. Built on 15 years of research, our easy-to-use PCR kit and proprietary cloud software deliver fast, actionable insights, improving patient outcomes and reducing healthcare costs. Backed by a strong competitive edge, expressTEC is leading the way in precision oncology.
Bio-tech Start Up
Founded by two women scientists
power of RNA analysis
Transform the way
eligibility testing is conducted
impacting the lives of breast cancer patients
Contributing to advancements in precision medicine
enabling clinicians to make informed treatment decisions
A better framework to clinicians